Share This Page
Drug Price Trends for NDC 71930-0074
✉ Email this page to a colleague
Average Pharmacy Cost for 71930-0074
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CARBAMAZEPINE ER 400 MG TABLET | 71930-0074-12 | 0.57848 | EACH | 2026-03-18 |
| CARBAMAZEPINE ER 400 MG TABLET | 71930-0074-12 | 0.60749 | EACH | 2026-02-18 |
| CARBAMAZEPINE ER 400 MG TABLET | 71930-0074-12 | 0.65965 | EACH | 2026-01-21 |
| CARBAMAZEPINE ER 400 MG TABLET | 71930-0074-12 | 0.71148 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 71930-0074
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Zepbound (tirzepatide) Market Analysis and Price Projections
Eli Lilly and Company's Zepbound (tirzepatide) entered the obesity market in late 2023, targeting a significant unmet need. The drug, already approved as Mounjaro for type 2 diabetes, offers a novel dual agonist mechanism targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This analysis provides an overview of Zepbound's market potential, pricing strategy, and competitive landscape.
What is Zepbound's Approved Indication and Mechanism of Action?
Zepbound is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease). The drug is administered via subcutaneous injection once weekly [1].
Tirzepatide’s dual agonist activity is central to its efficacy. By activating both GLP-1 and GIP receptors, it enhances insulin secretion, reduces glucagon secretion, slows gastric emptying, and increases satiety, leading to significant weight loss [2]. This dual action is a key differentiator compared to GLP-1 receptor agonists like semaglutide.
What is Zepbound's Dosing and Administration?
Zepbound is available in multiple dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg per 0.5 mL solution in a single-dose pen. The starting dose is typically 2.5 mg once weekly, with dose escalation every four weeks to minimize gastrointestinal side effects. The maximum recommended dose is 15 mg once weekly [1].
- Initial Dose: 2.5 mg once weekly
- Titration Schedule: Increase by 2.5 mg every four weeks as tolerated
- Maintenance Doses: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, or 20 mg once weekly
- Maximum Dose: 20 mg once weekly [1]
What is Zepbound's Pricing and Reimbursement Strategy?
Eli Lilly has established a list price for Zepbound that positions it competitively within the emerging obesity drug market, while also acknowledging the substantial investment required for chronic therapy.
The wholesale acquisition cost (WAC) for Zepbound is:
- $900 per month for a one-month supply of any dosage strength [3].
This pricing reflects the drug's clinical efficacy and the chronic nature of obesity treatment. Eli Lilly has also implemented programs to improve access and affordability for eligible patients.
Patient Assistance Programs:
- Savings Card Program: Eligible commercially insured patients can pay as little as $550 per month for a 1-month prescription, and $2,750 for a 6-month supply of Zepbound. This program is designed to reduce out-of-pocket costs for those with commercial insurance but high deductibles or co-pays [3].
- Lilly Cares Foundation: Provides free medication to eligible uninsured patients who meet certain income requirements and have no prescription drug coverage [4].
Reimbursement Landscape:
The reimbursement landscape for Zepbound is evolving. While payer coverage is expanding, it remains a significant factor influencing market penetration. Eli Lilly is actively engaging with payers to secure formulary placement and favorable coverage decisions. Initial payer coverage has been variable, with some insurers requiring prior authorization or restricting access based on specific clinical criteria. However, as clinical data matures and the demand for effective obesity treatments grows, broader coverage is anticipated.
What is the Competitive Landscape for Zepbound?
Zepbound enters a market with established and emerging competitors, primarily in the GLP-1 receptor agonist class.
Key Competitors:
- Novo Nordisk's Wegovy (semaglutide): The first FDA-approved GLP-1 receptor agonist specifically for chronic weight management. Wegovy has established significant market share and brand recognition. Its WAC is approximately $1,349 per month, making Zepbound’s list price lower [5].
- Novo Nordisk's Saxenda (liraglutide): An older GLP-1 receptor agonist, also approved for weight management. Saxenda is administered daily and generally shows lower weight loss efficacy compared to semaglutide and tirzepatide.
- Amylin Pharmaceuticals/AstraZeneca's CagriSema (semaglutide/cagrilintide): A combination therapy currently in late-stage development, aiming for potentially greater weight loss than semaglutide alone.
- Pfizer's danuglipron and danuglipron (oral GLP-1 receptor agonists): Pfizer is developing oral GLP-1 receptor agonists, which could offer an alternative administration route and potentially disrupt the market if they demonstrate comparable efficacy and safety. However, these are still in development and face challenges in achieving sufficient potency and tolerability for widespread use.
Comparative Efficacy and Pricing:
| Drug Name | Active Ingredient(s) | Mechanism | Indication | WAC (per month, approx.) | Average Weight Loss (%) | Launched (US) |
|---|---|---|---|---|---|---|
| Zepbound | Tirzepatide | GLP-1/GIP dual agonist | Chronic Weight Management | $900 | 15-22.5% (at 15mg/20mg doses) [6] | Nov 2023 |
| Wegovy | Semaglutide | GLP-1 receptor agonist | Chronic Weight Management | $1,349 | 12-17% (at 2.4mg dose) [7] | Jun 2021 |
| Saxenda | Liraglutide | GLP-1 receptor agonist | Chronic Weight Management | $1,000+ | 5-10% [8] | Dec 2014 |
Note: Weight loss percentages are based on clinical trial data and can vary significantly among individuals. Doses listed are the highest approved for weight management.
Zepbound's dual agonist mechanism has demonstrated superior weight loss efficacy in clinical trials compared to existing GLP-1 receptor agonists like semaglutide [6]. For instance, the SURMOUNT-1 trial showed mean weight loss of 22.5% for tirzepatide 15 mg compared to 12.4% for semaglutide 2.4 mg [6]. This superior efficacy, coupled with a lower list price than Wegovy, positions Zepbound as a strong contender.
What is the Market Size and Growth Potential for Zepbound?
The market for obesity treatments is substantial and projected to grow significantly. Factors driving this growth include increasing rates of obesity worldwide, growing patient and physician awareness of effective treatment options, and expanding payer coverage.
Market Drivers:
- Prevalence of Obesity: The Centers for Disease Control and Prevention (CDC) estimates that over 42% of U.S. adults are obese [9]. This represents a vast patient population.
- Clinical Efficacy: The high degree of weight loss achieved with tirzepatide offers a compelling treatment option for individuals seeking significant health improvements.
- Comorbidity Burden: Obesity is linked to numerous serious health conditions, creating a strong medical imperative for effective management.
- Payer Interest: As evidence of cost-effectiveness and improved patient outcomes emerges, payers are increasingly willing to cover these therapies.
Projected Market Size:
Estimates for the global obesity drug market vary, but most analysts predict substantial growth:
- 2023: Approximately $2.4 billion, largely driven by GLP-1 receptor agonists [10].
- By 2030: Projections range from $20 billion to over $100 billion [10, 11]. This wide range reflects uncertainties in adoption rates, new product launches, and pricing dynamics.
Eli Lilly has projected significant revenue from Zepbound and Mounjaro. In its Q4 2023 earnings report, Lilly noted that Mounjaro and Zepbound combined generated $5.07 billion in revenue for the full year 2023, with Zepbound launching in the last two months of the year [12]. Lilly anticipates these drugs to be key drivers of its future growth, with some analysts forecasting peak annual sales exceeding $25 billion for tirzepatide alone across both diabetes and obesity indications [13].
The primary market for Zepbound is adults seeking pharmacotherapy for weight management. The drug's strong efficacy data suggests it could capture a substantial share of this market, particularly from patients who have not achieved satisfactory results with or cannot tolerate existing therapies.
What are the Key Challenges and Risks for Zepbound?
Despite its promising outlook, Zepbound faces several challenges and risks that could impact its market trajectory.
Key Challenges:
- Payer Coverage and Access: Securing broad and consistent payer coverage remains critical. High co-pays or restrictive prior authorization requirements can limit patient access and uptake.
- Manufacturing Capacity: Eli Lilly must ensure it can scale up manufacturing to meet potentially explosive demand, avoiding shortages that could hinder market penetration and patient satisfaction.
- Competition: The GLP-1 market is increasingly crowded. Novo Nordisk has a significant first-mover advantage with Wegovy, and pipeline drugs from other major pharmaceutical companies pose future threats.
- Adverse Events: Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are common and can lead to treatment discontinuation. Long-term safety data will be crucial.
- Price Sensitivity: While the list price is lower than Wegovy, $900 per month is a significant cost for many individuals and healthcare systems. Price reductions or greater patient assistance may be necessary to maximize market penetration.
- Off-Label Use and Misinformation: The drug's efficacy may lead to off-label use for cosmetic purposes, which could attract regulatory scrutiny and potential supply diversions. Misinformation about efficacy and side effects can also impact patient adherence.
Risks:
- Clinical Outcomes in Real-World Settings: While clinical trials show high efficacy, real-world effectiveness may differ due to patient adherence, comorbidities, and variations in treatment protocols.
- Emergence of Superior Therapies: Breakthroughs in obesity pharmacotherapy or alternative treatment modalities could rapidly shift the competitive landscape.
- Regulatory Scrutiny: Post-market surveillance and potential regulatory actions related to safety or efficacy could impact Zepbound's market position.
- Economic Downturns: Reduced healthcare spending or increased patient financial strain during economic downturns could limit demand for expensive chronic therapies.
What are the Future Projections for Zepbound?
Zepbound is positioned to become a leading therapy in the obesity market, driven by its superior efficacy, dual-agonist mechanism, and a competitive pricing strategy relative to its primary competitor.
Projected Market Share:
Analysts forecast Zepbound to capture a significant share of the obesity market. Some estimates suggest it could reach annual sales of $10 billion or more within a few years, potentially rivaling or surpassing Wegovy [13]. Its success will hinge on its ability to demonstrate sustained real-world effectiveness, manage supply chains effectively, and navigate the complex payer landscape.
Key Growth Factors:
- Expanding Indications: Eli Lilly is investigating tirzepatide for other weight-related conditions, such as obstructive sleep apnea and cardiovascular risk reduction, which could further expand its market.
- Combination Therapies: Future research may explore combinations of tirzepatide with other agents to enhance weight loss or manage specific comorbidities more effectively.
- Global Expansion: Launching Zepbound in key international markets will be crucial for maximizing its global revenue potential.
The long-term success of Zepbound will depend on its ability to meet the evolving needs of patients and healthcare providers in a dynamic and increasingly competitive therapeutic area. The drug's robust clinical profile and Eli Lilly's strategic market entry suggest a strong trajectory for significant market impact.
Key Takeaways
- Zepbound (tirzepatide) offers a dual GLP-1/GIP agonist mechanism, demonstrating superior weight loss efficacy in clinical trials compared to existing GLP-1 receptor agonists.
- The drug is priced at a wholesale acquisition cost of $900 per month, which is lower than its primary competitor, Wegovy, and is supported by patient assistance programs.
- The global obesity drug market is poised for substantial growth, projected to reach tens of billions of dollars by 2030, driven by increasing obesity prevalence and demand for effective treatments.
- Key challenges for Zepbound include securing broad payer coverage, scaling manufacturing to meet demand, intense competition, and managing potential adverse events.
- Despite these challenges, Zepbound is projected to capture a significant market share and become a leading therapy in the obesity pharmacotherapy landscape.
Frequently Asked Questions
-
Will Zepbound be covered by Medicare and Medicaid? Medicare Part D does not currently cover weight-loss drugs, although this is subject to ongoing policy discussions. Coverage for Medicaid varies by state. Private insurance coverage for Zepbound is expanding but remains inconsistent, often requiring prior authorization and specific clinical criteria to be met [14].
-
What is the difference in effectiveness between Zepbound and Wegovy? Clinical trials have shown that tirzepatide (Zepbound) achieves statistically greater mean weight loss than semaglutide (Wegovy). For example, the SURMOUNT-1 trial reported up to 22.5% mean weight loss with tirzepatide 15 mg compared to 12.4% with semaglutide 2.4 mg [6].
-
What are the most common side effects of Zepbound? The most common side effects reported are gastrointestinal in nature, including nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. These side effects are typically dose-dependent and often resolve with dose adjustment or continued treatment [1].
-
Can Zepbound be used for type 2 diabetes management? Tirzepatide is also approved for type 2 diabetes management under the brand name Mounjaro. While Zepbound and Mounjaro contain the same active ingredient, Zepbound is specifically indicated for chronic weight management in adults with obesity or overweight and weight-related comorbidities, and Mounjaro is indicated for glycemic control in type 2 diabetes [1, 15].
-
How does Zepbound's dual agonist mechanism differ from single agonist GLP-1 drugs? Zepbound targets both GLP-1 and GIP receptors. GLP-1 primarily influences insulin secretion, gastric emptying, and satiety. GIP also enhances insulin secretion and may contribute to improved lipid metabolism and reduced appetite. The dual action is believed to enhance metabolic benefits and contribute to greater weight loss and glycemic control compared to drugs targeting only GLP-1 receptors [2].
Citations
[1] U.S. Food & Drug Administration. (2023, November 8). FDA approves new medication for chronic weight management. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management [2] DiPatrizio, M., & Jialal, I. (2023). Tirzepatide. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK561879/ [3] Eli Lilly and Company. (2023, November 8). Eli Lilly and Company Announces U.S. FDA Approval of ZEPBOUND™ (tirzepatide) for the Treatment of Chronic Weight Management. Retrieved from https://investor.lilly.com/news-releases/news-release-details/eli-lilly-and-company-announces-us-fda-approval-zepbound-tm/ [4] Lilly Cares Foundation. (n.d.). Get Help. Retrieved from https://www.lillycares.com/get-help/ [5] Novo Nordisk Inc. (n.d.). Pricing & Coverage. Retrieved from https://www.novonordisk.com/patients/wegovy/pricing-and-coverage.html [6] Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of adults with obesity. The New England Journal of Medicine, 387(3), 205-216. doi: 10.1056/NEJMoa2206038 [7] FDA. (2021, June 4). FDA approves new drug for chronic weight management. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-weight-management [8] Wilding, J. P. H., et al. (2014). Liraglutide 3.0 mg for the treatment of obesity: a randomized, double-blind, placebo-controlled trial. The Lancet, 384(9948), 1077-1086. doi: 10.1016/S0140-6736(14)61200-3 [9] Centers for Disease Control and Prevention. (2023, September 18). Adult Obesity Facts. Retrieved from https://www.cdc.gov/obesity/data/adult.html [10] Global Health & Pharma. (2023, December 11). The Obesity Drug Market: Trends, Challenges, and Future Outlook. Retrieved from https://www.ghpnews.com/the-obesity-drug-market-trends-challenges-and-future-outlook/ [11] Grand View Research. (2023, November). Obesity Drugs Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/obesity-drugs-market [12] Eli Lilly and Company. (2024, February 6). Eli Lilly and Company Reports Fourth Quarter and Full Year 2023 Results. Retrieved from https://investor.lilly.com/news-releases/news-release-details/eli-lilly-and-company-reports-fourth-quarter-and-full-year-2023-results/ [13] Reuters. (2024, February 6). Lilly’s Mounjaro, Zepbound sales $5.07 billion in 2023. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-mounjaro-zepbound-sales-hit-507-bln-2023-2024-02-06/ [14] U.S. Pharmacist. (2023, November 9). Zepbound Approved for Chronic Weight Management. Retrieved from https://www.uspharmacist.com/content/zepbound-approved-for-chronic-weight-management [15] U.S. Food & Drug Administration. (2022, May 5). FDA approves novel dual-acting GIP and GLP-1 receptor agonist tirzepatide. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-novel-dual-acting-gip-and-glp-1-receptor-agonist-tirzepatide
More… ↓
